COMPLETED

First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Conditions

Locally Advanced/Metastatic Solid Tumors

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

First-in-Human, Phase I, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of FL115 in patients with advanced solid tumors who have progressed or are intolerant to current standard-of-care therapies, including immune check-point inhibitors administered in single-agent or combination use.

Official Title

First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FL115 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumors

Quick Facts

Study Start:2023-12-30

Study Completion:2025-09-19

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT06130722

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Male or female ≥ 18 years 2. Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures 3. Histologically or cytologically confirmed incurable, unresectable, locally advanced or metastatic cancer that is refractory to standard therapies 4. Prior therapy: 5. Patient has at least 1 measurable target lesion or evaluable disease according to RECIST version 1.1 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 7. Patient's life expectancy ≥ 6 months 8. Adequate hepatic function as evidenced by meeting all of the following requirements: * Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN); or ≤ 5 × institutional ULN for patients who have serum bilirubin increases due to underlying Gilbert's Syndrome (familial benign unconjugated hyperbilirubinemia). * Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤ 2.5 × ULN; AST or ALT ≤ 5 × ULN if liver metastases are present 9. Adequate renal function as serum creatinine \< 1.5 × ULN and calculated creatinine clearance (CrCL) ≥ 60 mL/min (Cockcroft-Gault Equation). 10. Hematological function defined as: * Absolute neutrophil count ≥ 1,500/µL without growth factor support in the 2 weeks prior to study entry * Hemoglobin \> 9 g/dL without transfusion in the 2 weeks prior to study entry * Platelet count ≥ 100,000/µL without transfusion in the 2 weeks prior to study entry 11. Prothrombin (PT), international normalized ratio (INR), or activated partial thromboplastin time (aPTT) \< 1.5 × ULN; use of full dose anticoagulants is permitted. These laboratory test values should be maintained within the therapeutic range and closely monitored by the Investigator. 12. Female patients of childbearing potential and male patients with partners of childbearing potential agree to use a highly effective form(s) of contraception during study treatment that results in a low failure rate of \< 1% per year when used consistently and correctly. Male patients must always use a condom. Female patients of reproductive potential must not be pregnant, breastfeeding, or planning to conceive children within the duration of the study, beginning at the Screening visit (Initial Visit) through 120 days or for an additional 5 half-lives after the last dose of study treatment, whichever is longer. For female patients of reproductive potential, confirmation that the patient is not pregnant must be obtained by a negative serum pregnancy test result obtained during Screening. 13. Able to stay in a 24-hour inpatient unit after 1st infusion visit and subsequent dosing visits as needed.	1. Prior major surgery, chemotherapy, immunotherapy, or radiation therapy within 14 days prior to initiation of study treatment. No AE is evident from prior anticancer therapy except Grade 2 alopecia, sensory neuropathy, lymphopenia, and endocrinopathies controlled with hormone replacement. Palliative radiotherapy to a single area of metastasis is allowed (consult with assigned Medical Monitor) 2. Prior allogeneic stem cell, bone marrow, or solid organ transplant. 3. Live virus vaccine within 30 days prior to study entry 4. Known active autoimmune disease or history of autoimmune disease requiring systemic therapy within 2 years prior to entry; except hypothyroidism, vitiligo, Grave's disease, Hashimoto's disease, or Type 1 diabetes mellitus 5. Use of systemic corticosteroids in a dose equivalent to \> 10 mg/day of prednisone or other immunosuppressive agent within 2 weeks prior to study entry. Use of inhaled, topical, or ophthalmological steroids are allowed 6. Symptomatic CNS metastases. Patients with asymptomatic CNS metastases who are radiologically and neurologically stable ≥ 4 weeks following CNS directed therapy and are on a stable or decreasing dose of corticosteroids (e.g., prednisone less than 10 mg/day or equivalent) are eligible for study entry 7. Uncontrolled hypertension (systolic blood pressure \> 160 mmHg and diastolic blood pressure \> 99 mmHg), with symptoms or a known history of hypertension crisis, or hypertensive encephalopathy 8. Severe cardiovascular disease, including cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarction, or unstable angina within 6 months of study entry; New York Heart Association (NYHA) class III or IV heart failure within 6 months of study entry; uncontrolled arrhythmia within 6 months of study entry 9. Resting QTcF interval \> 470 msec on ECG at baseline; no concomitant medications that would prolong the QT interval; known family history of long QT syndrome. Left ventricular ejection fraction \<40% at baseline. 10. Concurrent malignancy within 2 years except cervical carcinoma in situ, localized squamous cell cancer of the skin, basal cell carcinoma, prostate cancer under active surveillance, ductal carcinoma in situ of the breast, or ≤ T1 urothelial carcinoma 11. Known active infection including HIV, hepatitis B or C, or tuberculosis, requiring active therapy; exceptions are as follows: * Patients infected with the HIV virus will be eligible if their CD4 count is \> 350 cells/mm3 and the patient is on anti-retroviral therapy with an HIV viral load that is below the level of detection. * Active Hepatitis B or C. HBV carriers without active disease (HBV DNA titer \< 1000 cps/mL or 200 IU/mL), or inactive Hepatitis C (negative HCV RNA test) may be enrolled. 12. Known or suspected hypersensitivity to FL115 or its excipients; known history of a Grade 3 or 4 allergic reaction to IL treatment or another fusion protein. 13. Women of childbearing potential who do not consent to use 2 highly effective methods of birth control (including 1 barrier method) during treatment and for an additional 5 half-lives or 120 days after the last administration of study drug, whichever is longer. 14. Men with a partner of childbearing potential who do not consent to use 2 highly effective methods of birth control (including 1 barrier method) during treatment and for an additional 5 half-lives or 120 days after the last administration of study drug, whichever is longer. 15. Any condition that the Investigator or primary physician believes may not be appropriate for the patient's participation in the study.

Inclusion Criteria

Exclusion Criteria

1. Male or female ≥ 18 years
2. Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures
3. Histologically or cytologically confirmed incurable, unresectable, locally advanced or metastatic cancer that is refractory to standard therapies
4. Prior therapy:
5. Patient has at least 1 measurable target lesion or evaluable disease according to RECIST version 1.1
6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
7. Patient's life expectancy ≥ 6 months
8. Adequate hepatic function as evidenced by meeting all of the following requirements:
* Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN); or ≤ 5 × institutional ULN for patients who have serum bilirubin increases due to underlying Gilbert's Syndrome (familial benign unconjugated hyperbilirubinemia).
* Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤ 2.5 × ULN; AST or ALT ≤ 5 × ULN if liver metastases are present
9. Adequate renal function as serum creatinine \< 1.5 × ULN and calculated creatinine clearance (CrCL) ≥ 60 mL/min (Cockcroft-Gault Equation).
10. Hematological function defined as:
* Absolute neutrophil count ≥ 1,500/µL without growth factor support in the 2 weeks prior to study entry
* Hemoglobin \> 9 g/dL without transfusion in the 2 weeks prior to study entry
* Platelet count ≥ 100,000/µL without transfusion in the 2 weeks prior to study entry
11. Prothrombin (PT), international normalized ratio (INR), or activated partial thromboplastin time (aPTT) \< 1.5 × ULN; use of full dose anticoagulants is permitted. These laboratory test values should be maintained within the therapeutic range and closely monitored by the Investigator.
12. Female patients of childbearing potential and male patients with partners of childbearing potential agree to use a highly effective form(s) of contraception during study treatment that results in a low failure rate of \< 1% per year when used consistently and correctly. Male patients must always use a condom. Female patients of reproductive potential must not be pregnant, breastfeeding, or planning to conceive children within the duration of the study, beginning at the Screening visit (Initial Visit) through 120 days or for an additional 5 half-lives after the last dose of study treatment, whichever is longer. For female patients of reproductive potential, confirmation that the patient is not pregnant must be obtained by a negative serum pregnancy test result obtained during Screening.
13. Able to stay in a 24-hour inpatient unit after 1st infusion visit and subsequent dosing visits as needed.

1. Prior major surgery, chemotherapy, immunotherapy, or radiation therapy within 14 days prior to initiation of study treatment. No AE is evident from prior anticancer therapy except Grade 2 alopecia, sensory neuropathy, lymphopenia, and endocrinopathies controlled with hormone replacement. Palliative radiotherapy to a single area of metastasis is allowed (consult with assigned Medical Monitor)
2. Prior allogeneic stem cell, bone marrow, or solid organ transplant.
3. Live virus vaccine within 30 days prior to study entry
4. Known active autoimmune disease or history of autoimmune disease requiring systemic therapy within 2 years prior to entry; except hypothyroidism, vitiligo, Grave's disease, Hashimoto's disease, or Type 1 diabetes mellitus
5. Use of systemic corticosteroids in a dose equivalent to \> 10 mg/day of prednisone or other immunosuppressive agent within 2 weeks prior to study entry. Use of inhaled, topical, or ophthalmological steroids are allowed
6. Symptomatic CNS metastases. Patients with asymptomatic CNS metastases who are radiologically and neurologically stable ≥ 4 weeks following CNS directed therapy and are on a stable or decreasing dose of corticosteroids (e.g., prednisone less than 10 mg/day or equivalent) are eligible for study entry
7. Uncontrolled hypertension (systolic blood pressure \> 160 mmHg and diastolic blood pressure \> 99 mmHg), with symptoms or a known history of hypertension crisis, or hypertensive encephalopathy
8. Severe cardiovascular disease, including cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarction, or unstable angina within 6 months of study entry; New York Heart Association (NYHA) class III or IV heart failure within 6 months of study entry; uncontrolled arrhythmia within 6 months of study entry
9. Resting QTcF interval \> 470 msec on ECG at baseline; no concomitant medications that would prolong the QT interval; known family history of long QT syndrome. Left ventricular ejection fraction \<40% at baseline.
10. Concurrent malignancy within 2 years except cervical carcinoma in situ, localized squamous cell cancer of the skin, basal cell carcinoma, prostate cancer under active surveillance, ductal carcinoma in situ of the breast, or ≤ T1 urothelial carcinoma
11. Known active infection including HIV, hepatitis B or C, or tuberculosis, requiring active therapy; exceptions are as follows:
* Patients infected with the HIV virus will be eligible if their CD4 count is \> 350 cells/mm3 and the patient is on anti-retroviral therapy with an HIV viral load that is below the level of detection.
* Active Hepatitis B or C. HBV carriers without active disease (HBV DNA titer \< 1000 cps/mL or 200 IU/mL), or inactive Hepatitis C (negative HCV RNA test) may be enrolled.
12. Known or suspected hypersensitivity to FL115 or its excipients; known history of a Grade 3 or 4 allergic reaction to IL treatment or another fusion protein.
13. Women of childbearing potential who do not consent to use 2 highly effective methods of birth control (including 1 barrier method) during treatment and for an additional 5 half-lives or 120 days after the last administration of study drug, whichever is longer.
14. Men with a partner of childbearing potential who do not consent to use 2 highly effective methods of birth control (including 1 barrier method) during treatment and for an additional 5 half-lives or 120 days after the last administration of study drug, whichever is longer.
15. Any condition that the Investigator or primary physician believes may not be appropriate for the patient's participation in the study.

Contacts and Locations

Study Locations (Sites)

HOAG Memorial Hospital Presbyterian

Newport Beach, California, 92663

United States

Moores Cancer Center at UCSD Health

San Diego, California, 92037

United States

Gabriel Cancer Center

Canton, Ohio, 44718

United States

Collaborators and Investigators

Sponsor: Suzhou Forlong Biotechnology Co., Ltd

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-30

Study Completion Date2025-09-19

Study Record Updates

Study Start Date2023-12-30

Study Completion Date2025-09-19

Terms related to this study

Additional Relevant MeSH Terms

Locally Advanced/Metastatic Solid Tumors